Pfizer Market Cap 2010-2024 | PFE

Pfizer market cap history and chart from 2010 to 2024. Market capitalization (or market value) is the most commonly used method of measuring the size of a publicly traded company and is calculated by multiplying the current stock price by the number of shares outstanding. Pfizer market cap as of February 28, 2025 is $151.03B.
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $151.025B $63.627B
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $835.717B 67.80
Novo Nordisk (NVO) Denmark $406.526B 27.53
Johnson & Johnson (JNJ) United States $394.223B 16.39
AbbVie (ABBV) United States $360.274B 20.17
Roche Holding AG (RHHBY) Switzerland $264.748B 0.00
Merck (MRK) United States $230.880B 11.95
Novartis AG (NVS) Switzerland $223.246B 13.98
Sanofi (SNY) $136.409B 12.92
Bayer (BAYRY) Germany $23.028B 3.69
Innoviva (INVA) United States $1.132B 9.42